BridgeBio Pharma and affiliate Origin Biosciences, are dedicated to commercializing Nulibry® (fosdenopterin) for injection, an approved treatment for molybdenum cofactor deficiency (MoCD) Type A.
We strive to deliver treatment to patients as quickly as possible because time is of the essence when facing the damage caused by this devastating disorder.